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Abstract
Study objective—There is little informa-
tion on the potential benefit of immunis-
ing all patients with chronic lung disease
in the community against influenza. The
clinical eVectiveness and economic ben-
efit was established of the influenza vacci-
nation programme in a general practice
based cohort of adult patients with
chronic lung disease followed up during
the 1995/96 influenza A epidemic.
Design—A prospective cohort study from
October 1995 to March 1996.
Setting—The study was undertaken in the
Utrecht General Practices Network with
six large group practices, covering a total
population of approximately 50 000 pa-
tients in the Netherlands.
Patients—Computerised medical records
of 1696 patients with chronic lung disease
aged over 18 years with an indication for
vaccination according to the Dutch GP
guidelines were reviewed.
Main results—The overall attack rate of
any complication, including all cause
death, low respiratory tract infection, and
acute cardiac disease was 15%. Exacerba-
tions of lung disease were most frequent
(13%). Death, pneumonia, and acute car-
diac disease were mainly limited to pa-
tients >65 years. No eVectiveness of the
immunisation programme could be estab-
lished in patients 18–64 years (n=1066),
after controlling for baseline prognosis in
multivariable logistic regression analysis.
In vaccinees>65 years (n=630), the occur-
rence of any complication was reduced by
50% (95% CI 17, 70%). The economic ben-
efit was estimated at £50 per elderly
vaccinee.
Conclusions—This study suggests that in
the Netherlands immunisation of elderly
patients with chronic lung disease against
influenza is eVective and cost-saving,
hence these patients should be given high
priority. More, preferably experimental,
studies are needed to establish whether
adult lung patients under 65 years in the
community will also benefit from vaccina-
tion.
(J Epidemiol Community Health 1998;52:120–125)
Although annual influenza vaccination has
been recommended to all patients with chronic
pulmonary disease,1 immunisation rates re-
main low, particularly in patients under 65.2–4
These low rates may only be partly the result of
concerns about side eVects, because many
studies have shown no serious adverse events.5–8
Scepticism about the impact of influenza in
non-institutionalised patients with chronic
lung disease is more likely to play an important
part. Currently, little information is available
on influenza related mortality and morbidity in
this group.9 Several studies have reported on
the eVectiveness of influenza vaccination, but
most were confined to elderly subjects with or
without chronic medical conditions.10–16 Only a
few studies included younger adults, and none
considered the eVectiveness in patients with
chronic lung disease alone.17–19 This apparent
lack of evidence of the potential health and
economic benefit resulting from immunising
all patients with chronic lung disease in the
community against influenza may explain the
poor immunisation rates.9 20
We aimed to assess the clinical eVectiveness
of an influenza vaccination programme in pre-
venting complications in adult patients with
chronic pulmonary disease. We therefore pro-
spectively followed up a general practice based
cohort of patients with lung disease from the
moment of vaccination until the end of the
influenza A epidemic of 1995/96. Because an
age based immunisation policy was recently
introduced in the Netherlands, after many
other countries,21 we considered its eVective-
ness in patients aged under and those aged over
65 years. Finally, we estimated direct costs of
medical care associated with the influenza epi-
demic and immunisation programme.
Methods
SETTING AND STUDY SUBJECTS
The Utrecht University General Practices Net-
work consists of six computerised group prac-
tices employing 23 general practitioners (GPs),
and covering about 50 000 patients living in
the central part of the Netherlands. Since
1989, clinical diagnoses and drug prescriptions
have been registered in the medical records
using ICPC codes,22 according to the
ICHPPC-2 criteria,23 and ATC codes,24 respec-
tively. Anonymous data were stored in a central
database. The initial step in the enrolment pro-
cedure consisted of a computerised search of
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all potential patients with chronic lung disease
in the period October 1993 to October 1995
using a software selection module.25 The search
was based on the following diagnoses: COPD
(chronic bronchitis/brochiectasis and emphy-
sema), asthma, malignant and benign neo-
plasm of the bronchus/lung, tuberculosis, pleu-
risy, congenital anomalies, and other diseases
of the respiratory system. In addition, patients
with drug prescriptions from the ATC-
subcategory R03 (adrenergics/other anti-
asthmatics) or with a “lung tag” indicating
chronic lung disease only were selected.
Participating GPs subsequently classified each
initially selected patient as indicated for vacci-
nation or not according to the guidelines of the
Dutch College of General Practitioners.26 All
selected high risk study subjects were invited
for vaccination in writing. Patients under 18
years with asthma were not part of our study
domain. Both risk of influenza related com-
plications and vaccine eVectiveness are diVer-
ent from that of adult patients with lung
disease.9 27
INFLUENZA VACCINATION
Mass vaccination of patients who complied
with the personal reminder took place in weeks
43 and 44 of 1995. The trivalent subunit
vaccine was based on H3N2 (A/Johannesburg/
33/94-like), H1N1 (A/Singapore/6/86-like),
and influenza B (B/Beijing/184/93-like)
strains.28 All vaccinees were registered.
THE 1995/96 INFLUENZA A EPIDEMIC
The influenza epidemic started in week 46
(1995) and ended in week 10 (1996).28 The
first and most important peak of influenza
activity was observed in December/January
and was associated with isolates of influenza
A(H3N2), whereas the second peak in Febru-
ary was small and mainly associated with influ-
enza A(H1N1) isolates. The vaccine composi-
tion largely matched viral strains isolated from
clinical samples collected by the Dutch Senti-
nel Practice network.28
DATA COLLECTION
Baseline information extracted from the medi-
cal records included age, sex, type of health
insurance, and the number of GP visits during
the 12 months before vaccination.Medical his-
tory data included diagnoses of lung disease
(see Setting and Study Subjects) and the
following diagnoses of high risk cardiac
comorbidity26 : angina pectoris, myocardial in-
farction, other chronic ischaemic heart disease,
heart failure, atrial fibrillation/flutter, paroxys-
mal tachycardia, ectopic beats, pulmonary
heart disease, heart valve disease, other heart
disease, and pulmonary embolism. Study
outcomes were all cause death, exacerbation of
pre-existent lung disease, pneumonia, conges-
tive heart failure, acute myocardial infarction,
and angina pectoris in week 46 (1995) to week
12 (1996).10–14 29 30 Acute low respiratory tract
illness (LRTI), including pneumonia and
Table 1 Baseline characteristics of study subjects (n=1696).Numbers and percentages (%) are given
Characteristic Non-vaccinees (n=453) Vaccinees (n=1243) p Value
Age category (y)
18–64 361 (80) 705 (57) < 0.001
> 65 92 (20) 538 (43)
Sex
Male 268 (59) 621 (50) < 0.001
Female 185 (41) 622 (50)
Health insurance
Private 191 (42) 406 (33) < 0.001
Sick fund* 262 (58) 837 (67)
Lung disease
Asthma† 282 (62) 595 (48) < 0.001
COPD‡ 171 (38) 648 (52)
Cardiac comorbidity§
No 425 (94) 1074 (86) < 0.001
Yes 28 (6) 169 (14)
Number of GP visits in previous 12 months
Low (<3) 383 (85) 923 (74) < 0.001
High (>3) 70 (15) 320 (26)
* Compulsory for patients with income lower than £21.50. † In this category patients with pleurisy, other unspecified neoplasm lung,
congenital anomalies, and other diseases of respiratory tract only are included (n=23). ‡ Chronic obstructive pulmonary disease (in
this category patients with neoplasm of lar/trac/bron/lung only are included, n=20). § ICPC codes K74–80, K82–84, K93 (see also
data collection).
Table 2 Outcome events (in %) by age category and vaccination status
Outcome event
18–64 years* > 65 years† All ages
Vac+ Vac− Vac+ Vac− Vac+ Vac−
LRTI/CD/death 12.0 9.7 20.8‡ 31.5 15.8 14.1
Low respiratory tract illness (LRTI)
Exacerbation 10.8 8.6 15.8 22.8 13.0 11.5
Pneumonia 1.1 0.8 1.9 3.3 1.3 1.3
Total LRTI 11.9 9.4 17.7 26.1 14.3 12.8
Cardiac disease (CD)
Congestive heart failure 0.0 0.3 2.0 3.3 0.9 0.9
Angina pectoris 0.0 0.0 0.6 1.1 0.2 0.2
Myocardial infarction 0.1 0.0 0.2 1.1 0.2 0.2
Total CD 0.1 0.3 2.8 5.4 1.3 1.3
* Based on n=1066. † Based on n=630. ‡ Including the deceased (n=8).
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exacerbations, was defined as the presence of
one or more of the following signs/symptoms
presented to the GP: (1) productive cough, (2)
wheezy breathing or (3) increased dyspnoea in
rest which led to the prescription of antibiotics,
â2 agonists or corticosteroids. Additional infor-
mation included hospitalisation, length of hos-
pital stay, and use of intensive care facilities. All
medical data were checked in the medical
records by a physician in April 1996.
STATISTICAL ANALYSIS
We dichotomised age into 18–64 or >65 years
(retirement age)1 and underlying lung disease
into COPD or asthma.9 We combined the out-
comes all cause death, acute LRTI, and cardiac
disease (CD) to form the primary outcome
measure. The two subsidiary outcome meas-
ures were any acute LRTI or CD. Univariate
analyses were performed to compare vaccinees
and non-vaccinees in baseline characteristics
using ÷2 tests for categorical variables and Stu-
dent’s t test for continuous variables.Multivari-
able logistic regression modelling (with
EGRET) was used to obtain adjusted estimates
and their 95% confidence intervals of vaccine
eVectiveness.10 14 31 In the first stage of con-
structing the model we defined the dependent
variable as presence or absence of the primary
outcome and the exposure term as vaccination
status. We allowed for the potentially con-
founding variables age, sex, health insurance,
lung disease defined as asthma or COPD, pres-
ence or absence of cardiac comorbidity, and
number of GP visits in the previous 12 months
and simultaneously added first order interac-
tion terms of these variables with vaccination
status and age. At this stage it became evident
that the interaction term age by vaccination
status contributed statistically significant to the
model, whereas other interaction terms did
not. We proceeded by constructing two sepa-
rate models for both age categories separately.
In the final models we only included those
variables that substantially changes the esti-
mate of vaccine eVectiveness. Regression diag-
nostics, including distributional and residual
plots, and assessment of outliers were used to
assess the robustness of the models. EVective-
ness was estimated using the formula:
(1−OR)×100%.11 We calculated Mantel-
Haenszel weighted relative risks (with EPI-
Info) to verify estimates using odds ratios with
frequent outcomes.
ECONOMIC ANALYSIS
We estimated direct costs of vaccination and
combined average costs of hospital stay and use
of intensive care facilities from a societal
perspective. Net savings were estimated as fol-
lows: net savings= immunisation costs (includ-
ing unit costs of vaccines and supplies, promo-
tion, delivery, vaccination, and overhead)−
costs of medical care averted. The number of
outcomes averted was calculated as follows: (N
vaccinees) × (attack rate of outcomes among
non-vaccinees) × (eVectiveness).11 Immunisa-
tion costs were estimated at £12.50 per person,
including supplies, promotion, delivery, vacci-
nation, and overhead. The estimation was
based on the total expenses of vaccination that
could be claimed by GPs in 1995. Expenses
were based on unit costs of vaccine (£4.60)
and delivery (£3.60), and £12.90 for patients
with private insurance, which equals £4.30 on
average for all patients. Costs of expenses (or
charges) were comparable with direct costs to
society. Costs of hospital stay (£168/day) and
intensive care facilities (£821/day) were based
on national data.32 To assess the eVects of vari-
ous estimates on the outcome of the economic
analysis, an optimal and worst case scenario
were established. We simultaneously varied
estimates of eVectiveness, proportion of pa-
tients needing medical care, and median length
of hospital stay over a plausible range of plus or
minus 20 per cent.
Results
The overall influenza vaccination rate in the
1696 study subjects was 73%. Age specific
immunisation rates were 66 (18–64 years) and
85% (>65 years). At baseline, vaccinees were
older (57 compared with 47 years, t value 10.5,
p<0.001), more often female, and insured
through the Sick Fund than non-vaccinees.
Also, COPD, cardiac comorbidity, and a high
Table 3 Attack rates, crude and adjusted odds ratios (OR), and estimated eVectiveness (adjusted %) by age category
(n=1696)
Outcome event
Attack rate
(%)
Vaccine
status
Crude OR
(95% CI)†
Adjusted OR*
(95% CI)
Adjusted eVectiveness*
(95% CI)
18–64 years (n=1066)
LRTI‡/CD§/death 12.0 Vac+ 1.28 (0.84, 1.94) 0.95 (0.62, 1.48) 5 (−48, 38)
9.7 Vac−
LRTI 11.9 Vac+ 1.30 (0.85, 1.98) 0.97 (0.63, 1.52) 3 (−52, 37)
9.4 Vac−
CD 0.1 Vac+ NA NA NA
0.3 Vac−
> 65 years (n=630)
LRTI‡/CD§/death 20.8 Vac+ 0.57 (0.35, 0.93) 0.50 (0.30, 0.83)** 50 (17, 70)
31.5 Vac−
LRTI 17.7 Vac+ 0.61 (0.36, 1.01) 0.54 (0.32, 0.93)*** 46 (7, 68)
26.1 Vac−
CD 2.8 Vac+ 0.50 (0.18, 1.41) 0.43 (0.15, 1.24) 57 (−24, 85)
5.4 Vac−
NA = not available. Numbers too small to construct a valid model. * Regression equation: outcome = â0+â1* (vaccine status) +
â2* (n, previous consultations) + â3* (underlying lung disease) + â4( (cardiac comorbidity). † 95% confidence intervals. ‡ Low res-
piratory tract illness, including exacerbations and pneumonia. § Cardiac disease, including acute congestive heart failure, myocar-
dial infarction and angina pectoris. ** Adjusted Mantel-Haenszel weighted relative risk 0.62 (95% CI 0.45, 0.86); variable GP visits
dichotomised (<3,>3) for stratification. *** Adjusted Mantel-Haenszel weighted relative risk 0.63 (95% CI 0.43, 0.91).
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GP visiting rate were more common among
vaccinees (table 1).
Overall, the attack rate of any complication
was 15%, mainly due to LRTI (14%). Exacer-
bations of underlying lung disease were most
frequently observed (12.7%). The occurrence
of death (0.5%), CD (1.3%), and pneumonia
(1.3%) was less frequent. The recorded
primary cause of death was cardiac heart
failure (3), pneumonia (2), pneumothorax,
cachexia, and ileus (n=8).
In patients aged 18–64 years, the attack rate
of any complication in vaccinees was slightly
higher than in non-vaccinees (table 2). Acute
CD and pneumonia were rarely observed, and
no deaths occurred. In contrast, the occurrence
of any complication in the elderly (>65 years)
was substantially higher, although less com-
mon in vaccinees than in non-vaccinees (21
compared with 32%).
Table 3 shows the results of the multivariable
analyses. In patients aged 18–64 years, no
eVectiveness of the immunisation programme
in reducing the occurrence of any complication
could be established, after adjustment for the
prognostic confounding variables underlying
lung disease, cardiac comorbidity, and number
of GP visits (adjusted OR 0.95, 95% CI 0.62,
1.48, table 3). The inclusion of the other base-
line variables age, sex, and health insurance did
not confound the association between out-
comes and vaccination status. Vaccination in
the elderly (>65 years) was associated with a
substantial reduction of the occurrence of any
complication (50%), any acute LRTI (46%), or
CD (57%, not statistically significant) after
adjustments. In patients with cardiac comor-
bidity (n=197), the eVectiveness in preventing
acute CD amounted even to 80% (95% CI 32
to 98%, data not shown).
In all, the hospitalisation rate was 1.8%. In
90% of hospitalised patients, one or more of
the following risk factors was present: age over
65 years, COPD, cardiac comorbidity, or a high
GP visiting rate. As vaccine eVectiveness could
only be demonstrated in patients>65 years, we
limited economic analyses to these subjects
(table 4). The hospitalisation rate in elderly
patients (including the deceased) with LRTI
was 9.2% and 45% for elderly with CD.
Median hospital stay due to LRTI was 10 days
(range 5–20 days) with 1.7% in intensive care,
while for CD it was 14 days (range 7–60 days)
with 15% in intensive care. In the scenario
analyses, we varied eVectiveness in preventing
LRTI from 26 to 66% and CD from 37 to
77%. Hospitalisation rates due to LRTI were
varied from 7.4 to 11% and CD from 36 to
54%, while median stay in hospital was varied
from 8 to 12 days and from 12 to 16 days,
respectively. After subtracting the mean vacci-
nation costs, we estimated the net savings to be
£50 (range from £16 to £101) per elderly vac-
cinee.
Discussion
The findings in this study suggest that
influenza vaccination is eVective and cost-
saving in elderly patients with lung disease, but
not in those aged under 65 years. However,
some issues need to be considered. Confound-
ing by indication is one of the important threats
when studying intervention eVects using an
observational design. As shown in our study,
vaccinees were at higher risk of developing
complications than non-vaccinees, which could
have led to an underestimation of the vaccine
eVectiveness. This confounding may therefore
have obscured a potential benefit in the
younger age group. Nevertheless, the immuni-
sation rate of 66% was high compared with
most other vaccination studies,10–14 which
probably reduces serious diVerences in base-
line prognosis. Also, the study population was
homogeneous with regard to indication criteria
and the prevalence of lung disease (36 of 1000)
was comparable with Dutch general practice
morbidity registration data (30–40 of
1000).26 33 Furthermore, we adjusted for some
important prognostic confounding variables.
The variable underlying lung disease was given
by subdividing patients into asthmatic patients
and COPD patients in accordance with other
studies.9 34 Misclassification of lung disease was
most probably very limited, because participa-
ting GPs were extensively trained in classifying
lung patients according to ICHPPC-2 criteria.
Health seeking behaviour and seriousness of
disease were also controlled for by the number
of previous GP visits.14 Nevertheless, we could
only adjust for known diVerences in vaccinees
and non-vaccinees. Complete comparability of
vaccinees and non-vaccinees with regard to the
prognosis of developing influenza related com-
plications can only be guaranteed in a ran-
domised placebo controlled trial.
We could not obtain valid information on
previous vaccinations. Some reports suggest a
reduced eVectiveness if patients are vaccinated
for the first time.16 17 As our GPs have been
immunising lung patients against influenza
since the early nineties, it is probable that most
vaccinees had been vaccinated more often.
Another possible limitation, like in all other
large eVectiveness studies,10–15 17 18 includes the
absence of laboratory confirmation of influ-
enza. A sensitive and non-specific definition of
clinical outcome may lead to an underestima-
tion of the eVectiveness.14 Although it has not
been reported yet, specificity of outcome
definitions may be higher in the elderly when
compared with the younger age group. This
might have contributed to the established
diVerences in eVectiveness. Our finding of no
eVectiveness in younger adults is in agreement
Table 4 Estimated direct costs (savings) associated with influenza vaccination per 100
vaccinated patients with chronic pulmonary disease (> 65 years) in the Netherlands
Outcome variable Estimated costs (in £)
Vaccination (£12.50 per vaccination) 1250
Medical care avoided for respiratory disease*
Hospital stay 1848
Intensive care 328
Medical care avoided for cardiac disease†
Hospital stay 3259
Intensive care 821
Net total savings 5007
* Based on 11 days hospital stay (100×0.261×0.46×0.092×10) and 0.4 days intensive care
(100×0.261×0.46×0.015×2) for LRTI per 100 vaccinees avoided. † Based on 19.4 days hospital
stay (100×0.054×0.57×0.45×14) and 1 day intensive care (100×0.054×0.57×0.15×2) for CD per
100 vaccinees avoided.
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with an earlier report by Wiselka and
colleagues3 who could not establish vaccine
eVectiveness in preventing exacerbations in
asthmatic patients aged 6 to 56 years during
the 1989/90 epidemic. Most exacerbations in
their study subjects were indeed thought to be
caused by viruses other than influenza A.
Beasley et al27 concluded that only in one third
of severe exacerbations in asthmatic patients
aged 15–56 years could a viral agent be identi-
fied. The potential impact of an immunisation
programme on the overall reduction of compli-
cations may be at stake when influenza is not
the causal agent. Two other cost-benefit studies
indicated no financial benefit from immunising
patients under 65 with various medical
conditions.19 35 The authors attributed this to
low death and hospitalisation rates in the
younger age group during an influenza epi-
demic. We observed no deaths in patients
under 65 and hospitalisation rates were 3.2
times lower in this group.
The inclusion of acute lung and heart disease
as it presents to the GP in the primary outcome
measure may be considered an important
advantage of this study. The burden of illness
could mainly be attributed to exacerbations of
pre-existing lung disease (13%), whereas a
minority of patients (2%) was hospitalised.
Studies in which hospitalisation and death are
the primary end points may suVer from more
serious selection bias, because hospitalisation is
mainly limited to patients with severe medical
conditions as shown in our study.
The fact that all deceased persons were vac-
cinated reflects a high immunisation rate in the
elderly subjects (85%). We were not able to
confirm influenza as the primary cause of
death, hence inferences about vaccination
status and mortality are diYcult.36 Our age
specific death rate of 1.3% in the elderly was
substantially lower than reported by Fleming et
al14 (3.0% in high risk elderly) and comparable
to rates reported by Nichol et al10 who included
mostly healthy non-institutionalised elderly.
Immunisation rates in these studies were lower
than in our study (10% and 58%, respectively).
The estimated vaccine eVectiveness of 50%
in the elderly is in accordance with a recently
published large meta-analysis,13 but net savings
seemed to be higher than reported earlier.10–12
As indirect costs resulting from work loss are
less important in the elderly, we only calculated
direct costs.10 Furthermore, we decided not to
add costs resulting from consultations for side
eVects, because only few such consultations
occurred in this study. Possible savings from
the reduced number of GP consultations and
drug use were even not taken into account.
Accordingly, our estimates of net savings may
be considered conservative.
Recently, Tirimanna and colleagues34
showed that more than half the patients with
asthma or COPD were not even known to the
GP. Although screening on lung function was
not part of this study, it is probable that elderly
patients with unknown lung disease could also
benefit from vaccination. An age based vacci-
nation policy may increase the likelihood of
reaching all elderly patients with known and
unknown high risk medical conditions in the
community.21
Our study suggests that in the Netherlands
the immunisation of elderly patients with
chronic lung disease against influenza is eVec-
tive and cost-saving. A population based strat-
egy should be developed so that these patients
can be identified and immunised eYciently.25
More, preferably experimental studies are
needed to establish whether adult patients with
lung disease under 65 years should be given
priority as well.
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